These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26861469)

  • 1. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
    Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the potential for QTc prolongation with avelumab.
    Vugmeyster Y; Güzel G; Hennessy M; Loos AH; Dai H
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1017-1026. PubMed ID: 31478078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
    Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
    Jewell RC; Mills RJ; Farrell C; Visser SAG
    Br J Clin Pharmacol; 2024 Oct; 90(10):2571-2581. PubMed ID: 38924122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
    Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
    Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
    Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
    Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
    Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
    Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
    Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
    Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
    Welch PA; Ng WT; Darstein CL; Musib L; Lesimple T
    J Clin Pharmacol; 2016 Jan; 56(1):101-8. PubMed ID: 26096682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
    Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.